Catalyst

Slingshot members are tracking this event:

Data from The Medicines Company's(MDCO) Phase 2 ORION 3 study of Inclisiran in Cardiovascular disease (ASCVD) Released

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MDCO

100%

Additional Information

Additional Relevant Details
  • Interim results from ongoing ORION-3 study demonstrated sustained lowering of LDL-C by more than 50 percent, with time-averaged absolute reductions of 59.4 mg/dL
  • No material safety issues observed in the study
  • Pivotal Phase 3 readouts for inclisiran expected in 3Q-2019 followed by regulatory filings expected in the U.S. in 4Q-2019 and Europe in 1Q-2020
https://www.themedic...
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 18, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Inclisiran, Orion Phase 2a Study, Cardiovascular Disease, Cholesterol Lowering